Tolerability of topiramate in children and adolescents
Article first published online: 19 AUG 2003
Journal of Paediatrics and Child Health
Volume 39, Issue 6, pages 416–419, August 2001
How to Cite
Reith, D., Burke, C., Appleton, D., Wallace, G. and Pelekanos, J. (2003), Tolerability of topiramate in children and adolescents. Journal of Paediatrics and Child Health, 39: 416–419. doi: 10.1046/j.1440-1754.2003.00180.x
- Issue published online: 19 AUG 2003
- Article first published online: 19 AUG 2003
- Accepted for publication 26 November 2002.
- adverse event;
Objective: To examine the tolerability of topiramate (TPM) in paediatric practice.
Methodology: A retrospective cohort study of patients aged less than 18 years commenced on TPM by paediatric neurologists. Patients were identified from the dispensing databases of two paediatric tertiary referral hospitals and from the authority prescription records of four paediatric neurologists. The clinical data were obtained from the patients’ medical records.
Results: There were 159 patients who were identified as having been commenced on TPM and follow-up data were available for 127 (80%) patients. The median (range) age at commencement of TPM was 8.1 (0.5−17.9) years, with 12 patients aged less than 2 years. After 4 years, 60% of patients had ceased the medication. Treatment limiting adverse effects included aggression/psychosis (n = 10), cognitive impairment/sedation (n = 6), anorexia/weight loss (n = 4) and desquamation (n = 1). Prior aggression (hazard ratio 5.91 (2.12−16.44)) and female gender (hazard ratio 2.94 (1.02−8.41)) were risk factors for ceasing TPM because of an adverse event. Thirty percent of children commenced on TPM experienced a treatment limiting adverse effect within 2 years of commencement.
Conclusions: The frequency of treatment limiting adverse events in children receiving topiramate is higher than previously reported.